For example, PPAR-γ agonists, which are used to treat type 2 diabetes, activate transcription factors to alter glucose metabolism and alleviate hyperglycemia.[45] These same agonists have also been tested in patients with MS because PPAR-γ and PPAR-α agonists also demonstrate anti-inflammatory properties.[46, 47]. This evidence concerns the gene PPARG and myeloid sarcoma.